Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Tim B. van der Houwen
Observed names:
T.B. van der Houwen,
Tim B van der Houwen,
Tim van der Houwen,
van der Houwen, Tim
Institutions:
Amsterdam UMC Location University of Amsterdam,
Amsterdam University Medical Centers,
Amsterdam institute for Immunology and Infectious Diseases,
University of Amsterdam
Observed institutions:
Erasmus MC,
Amsterdam UMC Location University of Amsterdam,
Amsterdam University Medical Centers,
Amsterdam institute for Immunology and Infectious Diseases,
University of Amsterdam
ORCID:
0000-0002-5896-7033
Observed ORCID:
0000-0002-5896-7033
OpenAlex ID:
A5062554397
Immunopathogenesis of Behçet's disease and treatment modalities
2022
·
T.B. van der Houwen
, P.M. van Hagen
, et al.
·
Seminars in Arthritis and Rheumatism
·
102
PDF
Behçet's Disease Under Microbiotic Surveillance? A Combined Analysis of Two Cohorts of Behçet's Disease Patients
2020
·
Tim B. van der Houwen
, Jan A. M. van Laar
, et al.
·
Frontiers in Immunology
·
60
PDF
B-Cell Dysregulation in Crohn's Disease Is Partially Restored with Infliximab Therapy
2016
·
Wilhelmina M. C. Timmermans
, Jan A. M. van Laar
, et al.
·
PLoS ONE
·
55
PDF
Behҫet’s Disease, and the Role of TNF-α and TNF-α Blockers
2020
·
Tim van der Houwen
, Jan van Laar
·
International Journal of Molecular Sciences
·
41
PDF
Leukocyte toll-like receptor expression in pathergy positive and negative Behçet’s disease patients
2020
·
Tim B van der Houwen
, Willem A Dik
, et al.
·
Rheumatology
·
25
PDF
Chronic signs of memory B cell activation in patients with Behçet’s disease are partially restored by anti-tumour necrosis factor treatment
2016
·
Tim B. van der Houwen
, P. Martin van Hagen
, et al.
·
Rheumatology
·
21
Real-world experience with targeted therapy in patients with histiocytic neoplasms in the Netherlands and in Belgium
2024
·
Paul G. Kemps
, F. J. Sherida H. Woei-A-Jin
, et al.
·
Blood Neoplasia
·
16
Long-term data on efficacy and safety of adalimumab in Behçet's disease
2023
·
T.B. van der Houwen
, B. Humer
, et al.
·
Clinical Immunology
·
14
Adalimumab provides long-lasting clinical improvement in refractory mucocutaneous Behçet's disease without formation of antidrug antibodies.
2019
·
Diana M Verboom
, Tim B van der Houwen
, et al.
·
PubMed
·
12
Characteristics of COVID-19 infection and antibody formation in patients known at a tertiary immunology department
2021
·
Niels A.D. Guchelaar
, Jan A.M. van Laar
, et al.
·
Journal of Translational Autoimmunity
·
8
PDF
Clinical course of COVID-19 infections in patients with Behçet's disease in the Netherlands
2021
·
A.A. Sophie den Otter
, Tim B. van der Houwen
, et al.
·
Clinical and Experimental Rheumatology
·
5
PDF
Porto-sinusoidal vascular disorder and nephrotic-range proteinuria due to venous vasculitis in Behçet's disease
2024
·
T.B. van der Houwen
, M.E. Annink
, et al.
·
Clinical Immunology
·
2
A pilot study into bosentan (Tracleer®) as an immunomodulating agent in patients with Behçet’s disease
2020
·
Tim B van der Houwen
, P Martin van Hagen
, et al.
·
Asian Pacific Journal of Allergy and Immunology
·
2
PDF
Chemotherapy or Immunotherapy in Behçet’s Disease?
2024
·
Jan A.M. van Laar
, Tim B. van der Houwen
·
NEJM Evidence
Can bosentan (Tracleer (R)) act as an immunomodulating agent in patients with Behcet's disease? A pilot study.
2018
·
Tim B. van der Houwen
, P. Martin van Hagen
, et al.
·
VUBIR (Vrije Universiteit Brussel)
Show more works
View as search
Works count:
16
Citation count:
363
H-index:
9
I10-index:
9
Year
Topic
Type